Emerging therapeutic options for the management of hepatitis C infection

World Journal of Gastroenterology

Volumn 20, Issue 23, 2014, Pages 7079-7088

  Richard Thompson, J ^a  

^a LIPSCOMB UNIVERSITY   (United States)

Author keywords

Cyclophilin inhibitors; Hepatitis C; Interferon; Pharmacotherapy; Polymerase inhibitors; Protease inhibitors; Ribavirin

Indexed keywords

ABT 450; ABT 450R; ACH 268; ACH 3102; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BILIRUBIN; BOCEPREVIR; DACLATASVIR; DANOPREVIR; DASABUVIR; DELDEPREVIR; FALDAPREVIR; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 28B; LEDIPASVIR; MERICITABINE; MIRAVIRSEN; MK 5172; OMBITASVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS-5 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; VIRUS PROTEIN;

ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DYSGEUSIA; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STEVENS JOHNSON SYNDROME; VIRUS INHIBITION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HOST PATHOGEN INTERACTION; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; RNA REPLICASE; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84902690006     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i23.7079     Document Type: Article

References (45)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171 [PMID: 15057920 DOI: 10.1002/hep.22759]
2. INCIVEK. Cambridge, MA: Vertex Pharmaceuticals Incorporated, 2011. Available from: URL: http://en.wikipedia. org/wiki/Vertex_Pharmaceuticals
3. VICTRELIS. Whitehouse Station, NJ: Schering Corporation, 2011. Available from: URL: http://www.accessdata.fda. gov/drugsatfda_docs/label/2012/020503s046lbl.pdf
4. PEGASYS®. Nutley, NJ: Hoffman-La Roche Inc. 2011. Available from: URL: http://www.manta.com/c/mmbpq0d/ hoffmann-la-roche-inc
5. PegIntron®. Whitehouse Station, NJ: Merck & Co., Inc., 2011. Available from: URL: http://www.merck.com/index. html
6. Tencate V, Sainz B Jr, Cotler SJ, Uprichard SL. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat Med 2010; 2010: 125-145 [PMID: 21331152]
7. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Kauffman R, Alam J, Jansen PL. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebocontrolled, randomized study. Gastroenterology 2006; 131: 997-1002 [PMID: 17030169]
8. Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640-648 [PMID: 17879366]
9. Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49: 163-169 [PMID: 18486984 DOI: 10.1016/j.jhep.2008.03.027]
10. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838 [PMID: 19403902 DOI: 10.1056/NEJMoa0806104]
11. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850 [PMID: 19403903 DOI: 10.1056/NEJMoa0807650]
12. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303 [PMID: 20375406 DOI: 10.1056/NEJMoa0908014]
13. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
14. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
15. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024 [PMID: 21916639 DOI: 10.1056/NEJMoa1014463]
16. U.S. Food and Drug Administration. Briefing Information for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee. Available from: URL: http://www.fda. gov/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AntiviralDrugsAdvisoryCommittee/ucm252559.htm
17. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709-1718 [PMID: 19787809 DOI: 10.1002/hep.23192]
18. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270-1278 [PMID: 17408662]
19. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716 [PMID: 20692693 DOI: 10.1016/ S0140-6736(10)60934-8]
20. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-618. e1-5 [PMID: 22626609 DOI: 10.1053/j.gastro.2012.05.011]
21. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
22. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
23. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012; 19: 449-464 [PMID: 22676357 DOI: 10.1111/ j.1365-2893.2012.01617.x]
24. Tanwar S, Trembling PM, Dusheiko GM. TMC435 for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2012; 21: 1193-1209 [PMID: 22616626 DOI: 10.1517/13543784. 2012.690392]
25. Manns PM, Poordad F. Simeprevir (TMC435) with peginterferon/ ribavirin for treatment of chronic HCV genotype 1 infection in treatment-resistant patients: results from QUEST-2 a phase III trial. Presented at 48th Annual Meeting of the European Association for the Study of the Liver; 2013 Apr 24-28; Amsterdam
26. Ferenci P, Asselah T, Foster GR. Faldaprevir plus pegylated interferon alpha-2A and ribavirin in chronic HCV genotype-1 treatment-naïve patients: final results from STARTVerso1, a randomized double blind placebo-controlled phase III trial. Presented at 48th Annual Meeting of the European Association for the Study of the Liver; 2013 Apr 24-28; Amsterdam
27. Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatmentnaïve patients with hepatitis C virus genotype 1 infection. Gastroenterology 2013; 145: 790-800. e3 [PMID: 23811112 DOI: 10.1053/j.gastro.2013.06.051]
28. Park JS, Chang DY, Kim JH, Jung JH, Park J, Kim SH, Lee YD, Kim SS, Suh-Kim H. Retrovirus-mediated transduction of a cytosine deaminase gene preserves the stemness of mesenchymal stem cells. Exp Mol Med 2013; 45: e10 [PMID: 23429359 DOI: 10.1016/j.jhep.2013.02.008]
29. Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013; 59: 18-23 [PMID: 23439262 DOI: 10.1016/j.jhep.2013.02.009]
30. Everson GT, Sims KD, Rodriguez-Torres M. Interim analysis of an interferon (IFN)-and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients. Presented at 48th Annual Meeting of the European Association for the Study of the Liver; 2013 Apr 24-28; Amsterdam
31. Manns M, Vierling JM, Bacon BR. High sustained viral response at 12-and 24-week follow-up of MK-5172 with pegylated interferon alfa-2b and ribavirin (PR) in HCV genotype 1 treatment-naive non-cirrhotic patient. Presented at 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013); 2013 Apr 24-28; Amsterdam
32. Lawitz E, Hill J, Vince B. ACH-2684 demonstrates potent viral suppression in genotype 1 hepatitis C patients with and without cirrhosis: safety, pharmacokinetic, and viral kinetic analysis. Presented at 48th Annual Meeting of the European Association for the Study of the Liver; 2013 April 24-28; Amsterdam
33. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hézode C, Lim JK, Bronowicki JP, Abrams GA, Bräu N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: 671-677 [PMID: 22714001 DOI: 10.1016/S1473-3099(12)70138-X]
34. Sulkowski MS, Gardiner DF, Rodriguez-Torres M. Sustained virologic response with daclatasvir plus sofosbuvir ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). Presented at 48th Annual Meeting of the European Association for the Study of the Liver; 2013 Apr 24-28; Amsterdam
35. Gane EJ, Stedman CA, Hyland RH. ELECTRON: 100% SVR rate for once-daily sofosbuvir plus ledipasvir plus ribavirin given for 12 weeks in treatment-naive and previously treated patients with HCV GT 1. Presented at 20th Annual Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3-6; Atlanta
36. HCV NS5A Inhibitor-ACH-3102. Available from: URL: http://www.achillion.com/ACH3102. Accessed Sep 28, 2013
37. Kowdley KV, Lawitz E, Poordad F. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267 and ABT-333 /-ribavirin in patients with chronic genotype 1 infection: results from the Aviator study. Presented at 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013); 2013 Apr 24-28; Amsterdam
38. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
39. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
40. Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, Dickson R, Tice A, Kulkarni R, Vierling JM, Lou Munson M, Chen YC, Najera I, Thommes J. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58: 514-523 [PMID: 23359491 DOI: 10.1002/ hep.26275]
41. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53 [PMID: 23281975 DOI: 10.1056/NEJMoa1208809]
42. Schultheiss C, Schauer T, Nahrstaedt H, Seidl RO. Evaluation of an EMG bioimpedance measurement system for recording and analysing the pharyngeal phase of swallowing. Eur Arch Otorhinolaryngol 2013; 270: 2149-2156 [PMID: 23440435 DOI: 10.2147/DDDT.S30946]
43. Flisiak R. Cyclophilin inhibitor alisporivir active against HCV in phase 2b, HBV in lab. Presented at 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011); 2011 Mar 30-Apr 3; Berlin
44. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-1694 [PMID: 23534542 DOI: 10.1056/NEJMoa1209026]
45. Muir A, Hillson J, Gray T. Peginterferon lambda-1a (Lambda) compared to peginterferon alpha-2a (Alfa) in treatment-naïve patients with HCV genotypes (GT) 1 or 4: SVR24 results from EMERGE Phase 2b. Presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 2012 Nov 9-12; Boston, MA